SGLT-2 Inhibitors, An Issue of Heart Failure Clinics

Deepak L. Bhatt, MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. A leading authority internationally on interventional cardiology in addition

Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk